Cell Stem Cell

Boston Medical Center Study Furthers Understanding of Lung Regeneration

Retrieved on: 
Monday, April 22, 2024
Mortality, Boston Medical Center, BMC, Cell Stem Cell, Cell, Chronic obstructive pulmonary disease, Boston University, Transplant, Regenerative medicine, Health, Bacteria, Respiratory disease, MD, Doctor of Philosophy, Disease, Respiratory system, Engineering, Acute respiratory distress syndrome, Pulmonary fibrosis, AT1, Science, Medicine, Knowledge, Infection, COPD, Vaccine

BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).

Key Points: 
  • BOSTON, April 22, 2024 /PRNewswire/ -- Researchers at Boston Medical Center (BMC) and Boston University (BU) today announced findings from a new research study, published in Cell Stem Cell, detailing the development of a method for generating human alveolar epithelial type I cells (AT1s) from pluripotent stem cells (iPSCs).
  • As science and medicine have progressed, researchers have identified a clear need for additional knowledge about lung cells to help improve patient health.
  • "Uncovering the ability to generate human alveolar epithelial type I cells (AT1s), and similar cell types, from pluripotent stem cells (iPSCs), has expanded our knowledge of biological processes and can significantly improve disease understanding and management," said Darrell Kotton, MD, Director, Center for Regenerative Medicine (CReM) of Boston University and Boston Medical Center.
  • This new study also furthers the CReM's goal of generating every human lung cell type from iPSCs as a pathway to improving disease management and provides a source of cells for future transplantation to regenerate damaged lung tissues in vivo.

Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 29, 2024
Neoplasm, CD47, VIVID, CD19, Exercise, Science Translational Medicine, Bone marrow, Lymphoid leukemia, Lupus nephritis, CTA, Biotechnology, Escape Room, Research and development, GLEAM, ANCA, GAAP, Sana, Insulin, Development, Immune system, Regeneration, ASH, CD22, AACR, B cell, Safety, Immunosuppression, Diabetes, Patent, IND, Insurance, Nature Biotechnology, NHL, Cancer, CLL, Contingency, Cell, NHP, Organoid, Autoimmunity, Administration, Cell Stem Cell, Patient, HIP, Nature Communications, ISSCR, C-peptide, Vaccine

The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.

Key Points: 
  • The Investigational New Drug Application (IND) cleared in 4Q 2023, and Sana expects to share initial data in 2024.
  • The Clinical Trial Application (CTA) cleared in 4Q 2023, and Sana expects initial data to be shared in the first half of 2024.
  • Non-GAAP research and development expense in 2023 excludes an expense related to the impairment of certain lab equipment and leasehold improvements, primarily due to the portfolio prioritization in the fourth quarter of 2023.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Iron Restriction Keeps Blood Stem Cells Young

Retrieved on: 
Friday, March 8, 2024
Bone marrow, Multimedia, Iron, Blood, Inflammation, Albert Einstein, Novartis, HSC, Ageing, Animal, Cell, Risk, B cell, University, Cell biology, Cell Stem Cell, Medicine, DRS, Research, Mouse

BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.

Key Points: 
  • BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.
  • "So basically, iron restriction governs and protects the regenerative capacity of stem cells—their ability to divide and to differentiate into blood cells," said the paper's co-corresponding author Yun-Ruei Kao, Ph.D. , research assistant professor of oncology and of medicine at Einstein.
  • Compared with controls, aged HSCs exposed to iron chelation produced significantly more blood cells after their HSCs were transplanted into other mice.
  • Dr. Will is currently exploring HSCs and iron from several angles: how to safely limit iron in HSCs during aging; whether restricting iron levels within HSCs can prevent their aging-associated transformation into cancerous HSCs; and to what extent other adult stem cells, such as those in the gut, depend on iron restriction to reliably regenerate tissues and organs.

Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP

Retrieved on: 
Tuesday, February 13, 2024
JDRF, Diabetes, Biotechnology, Regeneration, Doctor of Philosophy, IST, MD, Escape Room, Research, Behavior informatics, CD47, Cell, NHP, Organoid, Safety, Transplant, Immunosuppression, Cell Stem Cell, Patient, Insulin, HIP, T1D, Glucose, Pharmaceutical industry

SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has published a paper titled “Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate.” The paper evaluated a transplant of Sana’s engineered allogeneic, hypoimmune (HIP)-modified pancreatic islet cells into a fully immunocompetent, diabetic non-human primate (NHP). These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets). The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.

Key Points: 
  • These modified islet cells, which cluster into effective endocrine organoids, are termed “pseudo islet grafts” (p-islets).
  • The results demonstrated that the HIP-modified p-islets engrafted following intramuscular injection and provided stable endocrine function, enabling insulin independence in the absence of immunosuppression.
  • This publication, along with the ongoing IST, will provide invaluable insights toward our stem cell derived product candidate, SC451.
  • It was thus demonstrated that the tightly controlled blood glucose levels and insulin independence was entirely due to well-functioning HIP p-islets.

Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy

Retrieved on: 
Thursday, October 5, 2023
Interneuron, Neuropathology, Temporal lobe epilepsy, RNA, Clinical, Cell, GABAergic, B cell, DSM-IV codes, Survival, MGE, Generalized tonic–clonic seizure, Epilepsy, Transplant, Translation, GMP, Cell Stem Cell, Therapy, GABA, Seizure, Clinical trial, History, SAN, Tissue, Behavior informatics, Patient, Pharmaceutical industry, Vaccine, Sarcocystis neurona

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, today announced the publication of the development and characterization of a highly purified population of human stem cell-derived, pallial-specific MGE inhibitory interneurons for the potential treatment of focal epilepsy. In a preclinical study, administration of a single dose of the cells in a chronic model of drug-resistant MTLE resulted in durable and consistent suppression of focal seizures, as well as improvements in neuropathology and an increase in survival of the model. The study also demonstrated a potentially broad, safe and effective dosing range in the preclinical model. The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE (NCT05135091). The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online.

Key Points: 
  • The data support the development of Neurona Therapeutics’ regenerative cell therapy candidate, NRTX-1001, which is being evaluated in an ongoing Phase I/II clinical trial of a one-time dose in subjects with drug-resistant MTLE ( NCT05135091 ).
  • The preclinical data were published today in Cell Stem Cell as a Clinical and Translational Report titled “Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy” by first authors Bershteyn, Bröer, Parekh, Maury, and colleagues and is available online .
  • “We are thrilled to announce this landmark publication, which builds the foundation for NRTX-1001 and exemplifies the phenomenal science being conducted by Neurona employees.
  • The data support the development of Neurona’s cell therapy candidate NRTX-1001, which is being evaluated in an ongoing clinical trial ( NCT05135091 ) in adults with drug-resistant MTLE.

Research Paper Incorporating ProtoKinetix AAGP® Submitted to Scientific Journal for Publication

Retrieved on: 
Tuesday, June 6, 2023
Research, General Health, Technology, Clinical Trials, Science, Surgery, Nanotechnology, Biotechnology, Stem Cells, Other Science, Health, Diabetes, University of Alberta, FRCSC, Surgical oncology, University, AHS, MSM, Doctor of Philosophy, Organ transplantation, Cell Press, Cell Stem Cell, Canada Research Chair, Regenerative medicine, Blood, Cell, B cell, Immunosuppression, Medicine, Pharmaceutical industry, Dentistry

ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced the submission of a research paper describing cell characterization, graft evaluation, and yield of islet-like cells differentiated from patient-derived iPSCS for the treatment and eventual cure of Type-1 Diabetes for publication in Cell Stem Cell , a peer-reviewed scientific journal published by Cell Press.

Key Points: 
  • ProtoKinetix, Incorporated ( www.protokinetix.com ) (the "Company" or "ProtoKinetix") (OTCQB: PKTX ), a clinical-stage biomedical company, today announced the submission of a research paper describing cell characterization, graft evaluation, and yield of islet-like cells differentiated from patient-derived iPSCS for the treatment and eventual cure of Type-1 Diabetes for publication in Cell Stem Cell , a peer-reviewed scientific journal published by Cell Press.
  • ProtoKinetix has been working alongside Dr. James Shapiro and his lab to improve the yield of protocols to generate islets from stem cells.
  • Importantly, in addition to increasing yield, AAGP® did not negatively affect the quality of islet products.
  • AAGP® treated cells maintained similar characteristics and function to untreated cells but had improved product yield.

Top Discoveries from a Record-Breaking Year for Cincinnati Children's

Retrieved on: 
Wednesday, February 8, 2023
Cardiovascular disease, University, Stomach, Organoid, Vaccine, Mother, Pediatrics, Life, Infection, Immunity, The New England Journal of Medicine, Health, Cincinnati Children's Hospital Medical Center, Child, Risk, Cell Stem Cell, Student, Antibody, Pregnancy, MPH, Faculty, Date, Muscular dystrophy, COVID-19, Cancer, Mental health, Pharmaceutical industry, Nursing, Nature, MD

CINCINNATI, Feb. 8, 2023 /PRNewswire/ -- Even as research teams raced to study new vaccines and understand the potential impact of long-term COVID-19 symptoms, experts at Cincinnati Children's Hospital Medical Center made important discoveries during fiscal 2022 on a wide range of child health conditions including mental health, cancer, and many other diseases. 

Key Points: 
  • The latest Research Annual Report from Cincinnati Children's, one of the world's top pediatric academic medical centers.
  • The study , published in Cell Stem Cell, reflects the latest in a string of organoid medicine breakthroughs achieved at Cincinnati Children's.
  • They found five risk factors that count, and report that taking early steps to address those risks can pay off later in life.
  • Findings were published in The New England Journal of Medicine.

ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

Retrieved on: 
Thursday, August 4, 2022
Research, Hospitals, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPSC, DLBCL, Hospital, Chimeric antigen receptor T cell, CAR, Industry, CD19, EZH1, Mountaineering, CEO, Boston, Ecosystem, Technology, Cancer, CGMP, B-cell lymphoma, TCR, LLC, Potency (pharmacology), Canadian Aviation Regulations, Gene editing, Blood, Good manufacturing practice, Lymphatic system, Patient, Cell, Haematopoiesis, Cell Stem Cell, RNA, Drug development, Longevity, Adult, Vaccine, Pharmaceutical industry, Mobile phone

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs).

Key Points: 
  • ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs).
  • This is the first company to emerge from the previously announced five-year collaboration between Boston Childrens Hospital and ElevateBio to accelerate the development of novel cell and gene therapies.
  • CAR-T therapies have revolutionized the treatment of certain blood cancers, with complete responses in many patients undergoing this type of treatment.
  • In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities.

Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million

Retrieved on: 
Wednesday, July 13, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Technology, EQT, LSP, Biotechnology, Science, LinkedIn, Tumor microenvironment, Google Voice, Investment, GV (company), Invention, Patient, MOS, Cell Stem Cell, Drug discovery, Probability, COO, Founder, Medicine, EUR, Traction, Guild Education, FPV, Felicis Ventures, Cancer, Google Analytics, Oncology, Doctor of Philosophy, Growth, USD, Pharmaceutical industry, GV, Canva, Li Xilie

Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.

Key Points: 
  • Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.
  • Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.
  • The company will use the Series A funding to advance its proprietary MOS platform.
  • Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score for the clinic, enabling oncologists to make informed and timely treatment decisions.

Xilis Announces Series A Extension, Bringing Total Round to Over US$89 Million

Retrieved on: 
Wednesday, July 13, 2022
Other Health, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Technology, Mubadala Investment Company, Biotechnology, LinkedIn, Tumor microenvironment, Google Voice, Investment, GV (company), Patient, MOS, Cell Stem Cell, Drug discovery, Probability, COO, Physician, Founder, Traction, Guild Education, FPV, Felicis Ventures, Cancer, Google Analytics, Oncology, Doctor of Philosophy, Financial services, Pharmaceutical industry, GV, Canva, Li Xilie

Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.

Key Points: 
  • Xilis, Inc., a pioneering biotechnology company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, has closed an extension of over US$19 million to its Series A financing round, bringing the total amount raised to over US$89 million.
  • Our MOS technology is the first end-to-end, high-throughput patient-derived model drug discovery platform to identify drug candidates with a high probability of clinical success.
  • The company will use the Series A funding to advance its proprietary MOS platform.
  • Using MOS and AI-driven algorithms, Xilis is developing a Xilis Response Score for the clinic, enabling oncologists to make informed and timely treatment decisions.